ALS: Why It's So Hard to Treat

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Updated April 2026 | Medical Advisor: Nikhil Joshi, MD, FRCPC

ALS: Why It's So Hard to Treat

A plain-English guide to the biology behind amyotrophic lateral sclerosis — written for the caregivers and families who need to understand what's happening and why treatment is so challenging.

Nobody explains why ALS has so few treatment options. Your neurologist confirmed the diagnosis and talked about "managing progression," but didn't explain why — in a world where we can edit genes and cure hepatitis C — this disease remains so stubbornly resistant.

The gap between the severity of ALS and the modesty of available treatments is one of the most frustrating things you'll encounter. The answer isn't a lack of research effort. It's that the biology creates challenges that are genuinely formidable.

This is what they didn't have time to explain. The machinery of the disease itself, in plain English, so you can make sense of what you're seeing and ask better questions.

The London-to-Paris Cable: What Motor Neurons Are

To understand why ALS is so difficult, you first need to appreciate what motor neurons are and why they're so extraordinary — and so vulnerable.

A motor neuron is a specialized nerve cell whose job is to carry signals from your brain or spinal cord to your muscles. When you decide to move your hand, a signal travels from your brain down through the spinal cord and then along a motor neuron to the muscles of your hand. The motor neuron is the final link in the chain — the cable that connects the command center to the muscle that carries out the command.

Here's what makes motor neurons remarkable: they are among the longest cells in your body. A single motor neuron connecting your spinal cord to your foot can be over a meter long. To put this in perspective, imagine a cell body the size of a tennis ball. At that scale, the axon — the long fiber that extends from the cell body to the muscle — would stretch from London to Paris. That's the proportional length of some motor neurons.

This extraordinary length creates extraordinary demands. The cell body, where the nucleus lives and most proteins are made, has to supply and maintain this incredibly long cable. Nutrients, proteins, energy-producing structures, and signaling molecules all have to be manufactured in the cell body and transported down the entire length of the axon, like a supply line stretching from London to Paris. Waste and damaged components have to be transported back for recycling.

Motor neurons also fire frequently and intensely. Every voluntary movement requires rapid, repeated electrical signaling along these long cables. This electrical activity demands enormous amounts of energy, which means motor neurons need exceptionally active mitochondria — the tiny power plants inside cells that convert fuel to usable energy.

The result is a cell that operates at the extreme edge of biological capability. It's doing something remarkable — maintaining a meter-long cable, keeping it electrically active, and supplying it from a cell body that's microscopically small. But this remarkable capability comes with vulnerability. There's almost no margin for error. Any disruption to the internal transport system, energy production, or protein quality control is felt more acutely in a motor neuron than in almost any other cell type. Motor neurons are the world's most impressive biological cable — and the most fragile.

The Jammed Machinery: Protein Misfolding

Proteins are the workhorses of every cell. They carry out virtually every function — building structures, transporting materials, sending signals, generating energy. But a protein only works if it's folded correctly. Think of it like origami: a flat sheet of paper can become a crane, a boat, or a flower, but only if you make exactly the right folds in exactly the right order. A misfolded piece of origami is just crumpled paper.

In ALS, certain proteins misfold and begin to clump together. The most common of these is a protein called TDP-43, which is found in abnormal clumps in about 97% of ALS cases. In some familial (inherited) forms of ALS, a protein called SOD1 misfolds instead. In both cases, the misfolded proteins don't just stop working — they actively cause harm.

Imagine a factory assembly line. Normally, each worker (protein) does its job and the product moves along smoothly. Now imagine one worker starts malfunctioning and producing defective parts. If the factory's quality control catches the defective parts quickly, they can be removed and the line keeps running. But if the defective parts pile up faster than quality control can handle them, they start jamming the machinery. They clog the conveyor belts, block other workers from doing their jobs, and eventually grind the whole factory to a halt.

That's what happens inside a motor neuron with protein misfolding. The misfolded proteins aggregate — clump together — in ways that the cell's cleanup systems (called the proteasome and autophagy pathways) can't keep up with. These aggregates interfere with normal cellular functions. They block the transport systems that ship materials up and down the axon. They disrupt the function of mitochondria. They damage the cell's ability to process its own genetic instructions.

And here's what makes it truly insidious: there's evidence that misfolded proteins can cause neighboring normal proteins to misfold as well. It's like a contagion at the molecular level. One misfolded protein touches a normal one and corrupts it. This creates a spreading cascade that can overwhelm the cell's defenses over time. Some researchers believe this prion-like spreading may also explain how ALS progresses from one group of motor neurons to adjacent groups — the misfolded proteins propagating through the neural network like a chain of falling dominoes.

The Flood: Glutamate Excitotoxicity

Motor neurons communicate using chemical signals, and the most important of these is glutamate — the brain and spinal cord's primary excitatory neurotransmitter. When a signal needs to be sent, glutamate is released from one neuron, crosses a tiny gap called the synapse, and activates the next neuron. It's the fundamental language of the nervous system.

But glutamate is powerful, and like any powerful tool, it's dangerous in excess. Normally, after glutamate has delivered its signal, it's quickly swept up by surrounding cells — primarily support cells called astrocytes — and recycled. The system keeps glutamate levels tightly controlled because too much glutamate causes neurons to fire excessively, which triggers a cascade of internal damage.

Think of glutamate like water in a canal system. At the right level, it turns the waterwheels and powers the machinery. Too much, and it floods the works — the machinery runs too fast, overheats, and breaks down.

In ALS, the glutamate cleanup system becomes impaired. Astrocytes — the support cells responsible for mopping up excess glutamate — become dysfunctional (we'll discuss why in the next section). The result is that glutamate levels around motor neurons rise above safe levels. The motor neurons are chronically overstimulated — their electrical machinery is running too fast, burning through energy reserves, generating toxic byproducts, and accumulating internal damage.

This process is called excitotoxicity, and it specifically targets motor neurons because they have more glutamate receptors and are already operating at high metabolic intensity. Remember the London-to-Paris cable — these cells are already running at maximum capacity. The glutamate flood pushes them past their breaking point.

Excitotoxicity damages motor neurons through multiple mechanisms. It overloads them with calcium ions, which trigger destructive enzymes. It forces mitochondria to work beyond their capacity, leading to energy failure and the production of toxic free radicals. And it activates cell death pathways that, once started, are difficult to reverse.

One of the first drugs approved for ALS was designed to reduce glutamate signaling, and it does provide a modest benefit — extending survival by a few months on average. But it's addressing only one piece of a much larger puzzle, which is why its effect is limited. The glutamate flood is real and damaging, but it's not the only thing killing motor neurons.

The Neighborhood Problem: Non-Cell-Autonomous Disease

For years, researchers assumed that ALS was fundamentally a disease of motor neurons — that something went wrong inside the motor neuron, and if you could fix that internal problem, you could save the cell. This turned out to be only part of the story, and the rest of the story is one of the most important reasons why ALS is so hard to treat.

Motor neurons don't live alone. They're surrounded by a community of support cells, and the health of these neighbors turns out to be critical to motor neuron survival. The key players are:

This is what researchers mean when they call ALS a "non-cell-autonomous" disease. The problem isn't just inside the motor neuron — it's in the entire cellular neighborhood. Even if you could make a motor neuron completely healthy and resistant to internal problems, placing it in an ALS environment — surrounded by toxic astrocytes, aggressive microglia, and failing oligodendrocytes — would still cause it to die.

This has profound implications for treatment. It means that a drug targeting only the motor neuron's internal problems may not be enough. You also need to address the hostile environment created by the dysfunctional support cells. And each type of support cell may need a different intervention, because they're malfunctioning in different ways for different reasons.

It's like trying to save a house that's not only rotting from within but is also being undermined by a crumbling foundation, battered by hostile neighbors, and stripped of its insulation — all at the same time. Fixing any one problem helps a little, but the house remains in danger until all the problems are addressed.

The Transport Collapse

Remember the London-to-Paris cable. The motor neuron's axon needs a constant supply line from the cell body. This supply line runs on a system of molecular tracks — structures called microtubules that function like railroad tracks inside the cell. Motor proteins (yes, they're actually called "motor" proteins, though they have nothing to do with motor neurons by name) walk along these tracks carrying cargo — mitochondria, proteins, signaling molecules, and waste — in both directions.

In ALS, this transport system breaks down. The microtubule tracks can become damaged or disorganized. The motor proteins carrying cargo can be impaired. The cargo itself — particularly mitochondria, which need to be distributed along the entire length of the axon to provide energy — can become dysfunctional and pile up in the wrong locations.

Think of it as a highway system where the roads are crumbling, some trucks have broken engines, and the cargo is spoiled. Nothing gets where it needs to go. The far end of the axon — closest to the muscle — is the first to feel the supply shortage, because it's the farthest from the source. This is why ALS often manifests first as weakness in the extremities: the hands, feet, and tongue — all supplied by the longest motor neurons with the most extended supply lines.

The transport failure creates a vicious cycle. Without adequate mitochondria at the far end of the axon, local energy production drops. Without energy, the transport system itself cannot function (it requires energy to drive the molecular motors). This causes further transport failure, which worsens the energy crisis, which further degrades transport. The axon degrades from its tip backward — a pattern called "dying back" — and eventually the connection to the muscle is lost.

Once a motor neuron loses its connection to a muscle, neighboring healthy motor neurons initially try to compensate by sprouting new connections to the orphaned muscle fibers. This is why ALS can appear to plateau temporarily — the remaining neurons are picking up the slack. But these compensating neurons are now doing more work with the same limited resources, making them more vulnerable to the same disease process. Eventually, they too are overwhelmed.

Why ALS Has So Many Genetic Varieties

About 10% of ALS cases are clearly inherited (familial ALS), while the remaining 90% appear to occur without a clear genetic cause (sporadic ALS). But even within familial ALS, researchers have identified mutations in over 30 different genes that can cause the disease.

This genetic diversity means that "ALS" may actually be many different diseases that converge on the same final result: motor neuron death. Different genetic causes may trigger different initial problems — one mutation causes protein misfolding, another disrupts RNA processing, another damages mitochondria — but all roads lead to the same destination: a motor neuron that can no longer maintain itself.

This has important implications for treatment research. A drug developed based on one genetic form of ALS may not work for forms caused by different genetic mutations, because it's addressing a different initial trigger. And for the 90% of patients with sporadic ALS, where the trigger is unknown, it's even harder to know which molecular pathway to target.

It also means that clinical trials face a heterogeneity problem — the patients enrolled may have biologically different diseases, which makes it hard to detect a treatment effect that only works in a subset. A drug that helps 20% of ALS patients (those with a specific molecular subtype) might show no statistically significant benefit in a trial that includes all comers, because the effect is diluted by the 80% who have a different subtype.

Putting It All Together

ALS is difficult to treat because it's a convergence of problems that reinforce each other:

Each of these problems is being actively researched. Gene-targeted therapies are showing promise for specific genetic forms. Anti-inflammatory approaches aim to calm the hostile cellular neighborhood. New strategies for maintaining axonal transport are being developed. And the growing understanding that ALS is a multi-cell-type disease is driving combination treatment approaches.

The Progression

ALS typically progresses along a path — it may start in the hands, feet, or speech, then gradually affect more motor neurons. Breathing muscles are usually affected later. Understanding this progression helps with planning.

What Caregivers Can Take From This

If you're caring for someone with ALS, the biology matters because it explains the clinical reality:

Understanding the biology doesn't make ALS less devastating. But it can make the experience less bewildering — and give you a framework for evaluating information, asking questions, and making informed decisions alongside the medical team.

Questions to Bring to Your Doctor

Understanding the biology gives you better questions. Here are ones worth asking:

Our 14 AI research agents can analyze your specific situation across the full landscape of published research — finding connections your medical team may not have time to search for. It takes five minutes.

Frequently Asked Questions

Why are motor neurons specifically vulnerable in ALS?

Motor neurons are among the longest and most energy-demanding cells in the human body. A single motor neuron can extend from the brain or spinal cord all the way to a muscle in the foot — a distance of over a meter. Maintaining this enormous cell requires extraordinary amounts of energy, a complex internal transport system, and precise protein quality control. When any of these systems falter — due to protein misfolding, energy failures, or transport breakdowns — motor neurons are disproportionately affected because they have the least margin for error. Smaller, less demanding cells can tolerate the same problems more easily.

What does protein misfolding have to do with ALS?

Proteins must fold into precise three-dimensional shapes to function correctly. In ALS, certain proteins misfold and clump together inside motor neurons. These clumps are toxic — they clog the cell's internal machinery and interfere with normal functions. Worse, misfolded proteins can sometimes cause neighboring normal proteins to misfold as well, creating a spreading chain reaction. The cell has quality-control systems to catch and dispose of misfolded proteins, but when the rate of misfolding exceeds the cell's cleanup capacity, the toxic clumps accumulate and the cell begins to die.

Why does ALS spread from one body region to another?

ALS typically begins in one area — often a hand, foot, or the muscles of speech — and then progressively spreads to adjacent body regions. This spreading pattern has led researchers to hypothesize that the disease propagates along the neural network, potentially through the cell-to-cell spread of misfolded proteins. Think of it like a cascade of dominoes: once the first motor neurons are affected, the disease process spreads to connected neurons. This network-based progression, rather than random appearance of symptoms, is one of the distinctive features of ALS.

Why can't we just protect motor neurons from dying in ALS?

ALS is not solely a disease of motor neurons — it involves multiple cell types in the nervous system. Astrocytes (support cells), microglia (immune cells of the brain), and oligodendrocytes (insulation-producing cells) all become dysfunctional and contribute to motor neuron death. This is called the non-cell-autonomous nature of ALS. Even if you could make motor neurons resistant to the internal problems, the hostile environment created by surrounding dysfunctional cells would still cause damage. Effective treatment likely requires addressing problems in multiple cell types simultaneously.

Why do ALS treatments only slow the disease rather than stop it?

Current ALS treatments provide modest slowing of disease progression rather than a cure because they typically address only one of the many pathways contributing to motor neuron death. ALS involves protein misfolding, excessive glutamate signaling, mitochondrial dysfunction, inflammation, transport defects, and toxic contributions from non-neuronal cells — all happening simultaneously. Blocking one pathway may help somewhat, but the other pathways continue to cause damage. Until treatments can address multiple mechanisms at once, the effect of any single intervention is likely to remain limited.